Anthraquinone glycosides + Salicylic acid


Generic Medicine Info
Indications and Dosage
Mouth/Throat
Mouth ulcer
Adult: Available preparation:
Each mL of solution contains rhubarb extract 50 mg (containing 5 mg of anthraquinone glycosides) and salicylic acid 10 mg

In recurrent cases including ulcers resulting from dentures: Apply onto the affected oral mucosal area 3-4 times daily using a brush applicator. Max treatment duration: 7 days. Medical advice must be considered if no improvement is observed.
Child: ≥16 years Same as adult dose.
Contraindications
Children <16 years.
Special Precautions
Avoid frequent application (particularly in children). Not to be applied on dentures. Children ≥16 years. Pregnancy and lactation.
Adverse Reactions
Gastrointestinal disorders: Oral or tooth discolouration (temporary).
General disorders and administration site conditions: Burning sensation at the application site (transient).
Immune system disorders: Rarely, allergic reactions.
Action
Description: Anthraquinone glycosides reduce inflammation and salicylic acid is an analgesic. Given together, they exert actions, including antimicrobial, in all inflammatory lesions resulting to symptomatic relief of pain associated with recurrent mouth ulcers.
Storage
Store below 25°C.
MIMS Class
Preparations for Oral Ulceration & Inflammation
References
Joint Formulary Committee. Salicylic Acid with Rhubarb Extract. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 04/08/2020.

Pyralvex Solution (Interphil Laboratories Inc). MIMS Philippines. http://www.mims.com/philippines. Accessed 04/08/2020.

Pyralvex Solution, Oromucosal Solution (Mylan Products Ltd.). MHRA. https://products.mhra.gov.uk/. Accessed 04/08/2020.

Disclaimer: This information is independently developed by MIMS based on Anthraquinone glycosides + Salicylic acid from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in